ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) lifting 0.61%.
Healthcare is seen as a defensive sector.
In today's turbulent market, perhaps you might be looking for buying opportunities?
Here are four recommendations from the professionals.
Dylan Evans from Catapult Wealth has a buy rating on this ASX 200 biotech giant.
Evans told The Bull:
Threats from the Trump Administration to extend tariffs to imported pharmaceuticals would possibly have a negative impact on CSL, given it generates around half its revenue in the US.
Despite these risks, we believe CSL represents good value.
It remains a high quality company, delivering double digit earnings growth. It looks cheap compared to global peers.
The impact of US tariffs is factored into the share price, so, in our view, there's upside potential if they are withdrawn, or lower than anticipated.
CSL shares closed at $245.43 on Tuesday, up 0.47% today and down 10.8% over the past year.
Jed Richards from Shaw and Partners says ASX 200 healthcare share, Resmed, is a buy.
He liked what he saw in the sleep apnoea device maker's latest report.
Richards said:
On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent.
ResMed's innovative products and steady revenue growth make it a solid investment.
The Resmed share price closed at $36.75, down 0.49% on Tuesday and up 12.6% over the past year.
John Athanasiou from Red Leaf Securities has a buy rating on diagnostic pathology and imaging company, Healius.
Athanasiou said:
The company is focusing on strengthening its core pathology operations.
Growth in test volumes, driven by an ageing population and increased demand for complex diagnostics, should support margin expansion — particularly as Healius invests in automation and artificial intelligence to reduce costs.
This ASX 200 healthcare share finished the session on Tuesday at $1.44, up 2.9% for the day and up 18.9% over the past 12 months.
Bell Potter has a buy rating on Telix Pharmaceuticals shares after the biotech reported strong revenue in the March quarter.
For the three months ended 31 March, Telix reported unaudited revenue of approximately US$186 million.
This was a 62% increase over the previous 12 months and a 31% bump over the December quarter.
The broker has a 12-month share price target of $36 on Telix Pharmaceuticals shares.
The ASX 200 healthcare share finished Tuesday's session at $26.95, up 1.01% for the day and up 74% over the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.